Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which prostate radiation is easier on patients? new trial aims to find out

NCT ID NCT03426748

Disease control Sponsor: British Columbia Cancer Agency Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two radiation methods for men with low- or intermediate-risk prostate cancer: low dose rate (permanent seed implants) and high dose rate (temporary radioactive needles). The main goal is to see which approach better preserves urinary quality of life. About 140 men will be followed for up to 5 years to track side effects and recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy (low dose rate or high dose rate brachytherapy)
What this could lead to
If this trial succeeds, it could show which brachytherapy method causes fewer urinary side effects while controlling prostate cancer equally well.
What could go wrong
This is an early-stage comparison with 140 participants, so results may not apply to all patients. Both treatments involve radiation risks like urinary or bowel problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

140 people

The number who actually took part.

Started

Feb 2018

Expected to finish

Oct 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Favorable risk and low-tier intermediate-risk prostate cancer with estimated life expectancy of at least 10 years. * Clinical stage T1c-T2b, PSA \< 20, Gleason \< 8 * ECOG 0-1 * Low tier intermediate-risk prostate cancer is defined by a single NCCN intermediate risk factor * Extensive favorable-risk disease is defined as: * clinical stage T1c-T2a * PSA \< 10 * Gleason 6 * ≥ 50% of biopsy cores containing cancer * PSA density \> 0.2 ng/cc * Selected intermediate risk patients not defined above * \- T1c/T2a * \- PSA \< 10 * -Gleason 4+3 * PSA \> 10 and Gleason 3+4 * PSA 10-15 ng/ml and Gleason 4+3 * -\< 33% of cores involved * -Max tumor length in any core 10 mm * No androgen deprivation therapy (ADT) * Prostate volume by TRUS ≤ 60 cc. * Not eligible for, or accepting of, active surveillance according to NCCN guidelines. * Signed study specific informed consent. Exclusion Criteria: * Prior radical surgery for carcinoma of the prostate, * Prior pelvic radiation * Prior chemotherapy for prostate cancer, * Prior TURP or cryosurgery of the prostate * Claustrophobic or unable to undergo MRI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • British Columbia Cancer Agency Center for the Southern Interior

    Kelowna, British Columbia, V1Y5L3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.